References
- Oikonomopoulou C, Goussetis E. HSCT remains the only cure for patients with transfusion - dependent thalassemia until gene therapy strategies are proven to be safe. Bone Marrow Transplant. 2021; 56(12): 2882 - 2888. https://doi.org/10.1038/s41409-021-01461-0 PMid:34531544
- Yesilipek MA et al. Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience. Bone Marrow Transplant. 2022;57(5):760-767. https://doi.org/10.1038/s41409-022-01613-w PMid:35210564
- Locatelli F, Merli P, Strocchio L. Transplantation for thalassemia major: alternative donors. Curr Opin Hematol. 2016;23(6):515-523. https://doi.org/10.1097/MOH.0000000000000280 PMid:27537474
- Santarone S et al. Survival and late effects of hematopoietic cell transplantation in patients with thalassemia major. Bone Marrow Transplant. 2022; 57:1689-1697. https://doi.org/10.1038/s41409-022-01786-4 PMid:36002533 PMCid:PMC9400570
- EUR-Lex. 32016L1214-EN-EUR-Lex. Available at: https://eurlex.europa.eu/eli/dir/2016/1214/oj/eng
- Cappelli B et al. Risk factors and outcomes according to age at transplantation with an HLAidentical sibling for sickle cell disease. Haematologica. 2019;104(12):e543-6 https://doi.org/10.3324/haematol.2019.216788 PMid:31018975 PMCid:PMC6959194
- Cappelli B et al.The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet]. 8th edition. Cham (CH): Springer, 2024; 80.
- Lüftinger R et al. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major. Ann Hematol. 2022;101(3):655-665. https://doi.org/10.1007/s00277-021-04732-4 PMid:34999929
- Chen H et al. Prediction, management, and prognosis of mixed chimerism after hematopoietic stem cell transplantation in transfusion - dependent pediatric thalassemia patients. Pediatr Transplant. 2020;24(8):e13876. https://doi.org/10.1111/petr.13876 PMid:33098346
- Susu Gong et al. Uniform Graft-versus-Host Disease Prophylaxis using Post -Transplantation Cyclophosphamide, Methotrexate, and Cyclosporine following Peripheral Blood Hematopoietic Stem Cell Transplantation from Matched and Haploidentical Donors for Transfusion-Dependent Thalassemia: A Retrospective Report from the Bone Marrow Failure Working Group of Hunan Province, China. Transplantation and Cellular Therapy, 2024. https://doi.org/10.1016/j.jtct.2024.08.022 https://doi.org/10.1016/j.jtct.2024.08.022 PMid:39236789